# NX Pharmagen Inc.: Form D filings

NX Pharmagen Inc., a biotechnology company in Louisville, KY, filed 4 Form D notices with the SEC between 2010 and 2022. The latest, on October 21, 2022, reports $590,000 sold of a $1 million offering to 19 investors.

Find out what NX Pharmagen Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.

- [Watch for new raises](https://specstream.ai/workspace/ask?q=Tell%20me%20when%20NX%20Pharmagen%20Inc.%20files%20a%20new%20Form%20D%20or%20reports%20more%20money%20sold%2C%20with%20the%20filing&src=data-formd&kind=alert&entity=NX%20Pharmagen%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Fnx-pharmagen-inc-1508691)
- [Get founders and investors](https://specstream.ai/workspace/ask?q=For%20NX%20Pharmagen%20Inc.%2C%20find%20what%20the%20company%20does%2C%20its%20website%2C%20the%20founders%20and%20executives%20with%20their%20LinkedIn%20and%20work%20email%2C%20its%20investors%20and%20every%20funding%20round%20with%20the%20amounts%2C%20its%20headcount%20and%20any%20reported%20valuation&src=data-formd&kind=record&entity=NX%20Pharmagen%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Fnx-pharmagen-inc-1508691)

## The full lists

This record is a row of these lists. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email.

- [Form D filings in Kentucky](https://specstream.ai/data/form-d/state/kentucky): 216 rows, by operating companies, filed since November 1, 2024, $10.80, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/state/kentucky
- [Form D filings in Biotechnology](https://specstream.ai/data/form-d/industry/biotechnology): 1,568 rows, by operating companies, filed since November 1, 2024, $78.40, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/industry/biotechnology

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

## Company details from the filing

- Address: 4350 BROWNSBORO ROAD, SUITE 110, Louisville, KY, 40207
- Phone: (502) 893-4570
- Industry: Biotechnology
- Entity type: Corporation
- Incorporated in: Delaware
- Revenue range: Decline to Disclose
- Exemptions claimed: Rule 506(b)
- SEC identifier (CIK): 1508691

## Form D filings

| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Oct 21, 2022 | New notice | $1,000,000 | $590,000 | $410,000 | 19 | Oct 10, 2022 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1508691/000150869122000001/0001508691-22-000001-index.htm) |
| Aug 31, 2020 | New notice | $1,000,000 | $486,000 | $514,000 | 13 | Aug 17, 2020 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1508691/000150869120000003/0001508691-20-000003-index.htm) |
| Jun 25, 2013 | New notice | $1,000,000 | $773,000 | $227,000 | 0 | Jun 24, 2013 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1508691/000091195913000023/0000911959-13-000023-index.htm) |
| Dec 28, 2010 | New notice | $1,500,000 | $0 | $1,500,000 | 0 | Yet to occur | [sec.gov](https://www.sec.gov/Archives/edgar/data/1508691/000091195910000041/0000911959-10-000041-index.htm) |

## Executive officers and directors named in the filing

| Name | Role | Note in the filing |
| --- | --- | --- |
| Alan Ezrin | Director |  |
| Brian Brohman | Executive Officer, Director |  |
| Robert Saunders | Director |  |

[Every Form D from the week of Oct 17, 2022](https://specstream.ai/data/form-d/week/2022-10-17) · [All recent filings in Kentucky](https://specstream.ai/data/form-d/state/kentucky) · [All recent Biotechnology filings](https://specstream.ai/data/form-d/industry/biotechnology)

Read from SEC EDGAR. Amount sold is what NX Pharmagen Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).